Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® ...

Johnson And Johnson Weighs Drug Breakthroughs Against Possible DePuy Synthes Sale

Johnson & Johnson (NYSE:JNJ) reported encouraging early clinical results for its prostate cancer therapy pasritamig and is preparing for Phase 3 trials. The company has submitted nipocalimab to the ...
Monthly Prescribing Reference

Rilzabrutinib Gets Breakthrough Status for Warm Autoimmune Hemolytic Anemia

Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...
manilatimes

Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia

Paris, February 9, 2026. The US Food and Drug Administration (FDA) has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) ...
Hosted on MSN

Avoid garlic: Essential guide to keep your dog safe and healthy

Discover the reasons why garlic is dangerous for dogs. Learn to recognize the symptoms to protect your furry friends. Many dog owners are concerned about what is safe for their dogs to eat, ...

60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODA

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) is one of the best up and coming penny stocks to buy. On February 2, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to enhance the ...

Sanofi Wins U.S. Breakthrough and Japan Orphan Status for Rilzabrutinib in Rare Anemia

On February 9, 2026, Sanofi announced that its oral BTK inhibitor rilzabrutinib, marketed as Wayrilz for immune thrombocytopenia, received U.S. FDA breakthrough therapy designation and orphan drug ...
The American Journal of Managed Care

Sickle Cell Disease FAQ: Subtypes, Current Therapies, and Access Challenges

Sickle cell anemia (HbSS) is the homozygous dominant variant and the most common and severe form of the disease. Whereas patients who only inherited one gene encoding for abnormal HbS and a different ...

CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...
Rock News

Warm Autoimmune Hemolytic Anemia Waiha Treatment Market to Witness Huge Growth by 2033

The Warm Autoimmune Hemolytic Anemia Waiha Treatment Market plays a crucial role in modern hematology by enabling more precise and effective treatment options. It supports the development of novel ...

Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript

Fulcrum Therapeutics, Inc. ( FULC) Q4 2025 Earnings Call February 24, 2026 8:00 AM EST Good morning, and welcome to the Fulcrum Therapeutics conference call to discuss 12-week data from the ...
Le Lézard

DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference

DaVita Inc.  today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD ...